Case Report: Complete metabolic responses to trastuzumab–deruxtecan in HER2-altered solid tumors: two illustrative cases
BackgroundHuman epidermal growth factor receptor-2 (HER2) alterations, including activating mutations and gene amplification, are emerging therapeutic targets in several solid tumors. Trastuzumab–deruxtecan (T-DXd), a HER2-directed antibody-drug conjug…